Motif Bio plc IPO Info
Company Name: Motif Bio plc
Stock Symbol: MTFB
Exchange: NASDAQ
Status: Priced
IPO Date: 11/18/2016
IPO Price:
6.98 (
-11.32%)
Underwriters
H.C. Wainwright
Amount of Offering: N/A
Number of Shares Offered: 2.44 Mil
Shares Outstanding After Offering: N/A
Valuation: N/A
Company Description
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (REVIVE-1 and REVIVE-2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.
News Headlines
